Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:FDA
gptkb:EMA |
| gptkbp:clinical_trial |
gptkb:granulomatosis_with_polyangiitis
gptkb:microscopic_polyangiitis gptkb:healthcare_organization gptkb:rheumatoid_arthritis ongoing autoimmune diseases |
| gptkbp:contains |
monoclonal antibodies
|
| gptkbp:contraindication |
active infections
severe hypersensitivity history of progressive multifocal leukoencephalopathy |
| gptkbp:developed_by |
gptkb:Rituximab
|
| gptkbp:dosage_form |
varies by indication
|
| gptkbp:education |
follow-up appointments
recognizing side effects importance of adherence |
| gptkbp:formulation |
gptkb:item
|
| gptkbp:frequency |
every few weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rituximab biosimilars
|
| gptkbp:interacts_with |
immunosuppressants
live vaccines other biologics |
| gptkbp:invention |
off-patent
|
| gptkbp:is_compared_to |
original Rituximab
|
| gptkbp:is_compatible_with |
original Rituximab
|
| gptkbp:is_monitored_by |
blood tests
vital signs |
| gptkbp:manager |
IV
|
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:marketed_as |
multiple countries
various brand names |
| gptkbp:pharmacokinetics |
adverse event reporting
C D20 targeting variable half-life |
| gptkbp:population |
adults
pediatric patients |
| gptkbp:provides_information_on |
ASCO guidelines
NCCN guidelines |
| gptkbp:regulatory_compliance |
approved
|
| gptkbp:research_areas |
oncology
rheumatology |
| gptkbp:research_focus |
efficacy studies
safety studies cost-effectiveness studies |
| gptkbp:sales |
growing
|
| gptkbp:serves |
gptkb:healthcare_organization
gptkb:non-Hodgkin_lymphoma |
| gptkbp:side_effect |
fatigue
headache nausea diarrhea rash cardiovascular events infections infusion reactions hypersensitivity reactions tumor lysis syndrome |
| gptkbp:supply_chain |
cold chain management
|
| gptkbp:used_in |
oncology
|
| gptkbp:bfsParent |
gptkb:Rituximab
|
| gptkbp:bfsLayer |
5
|